Latest Greg Winter Stories
COPENHAGEN and OSLO, September 1 /PRNewswire-FirstCall/ -- Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that it has appointed two experienced biotech executives to head its management team. Dr Robert Burns, previously CEO of Celldex Therapeutics Inc., has today assumed overall responsibility for Affitech as its new Chief Executive Officer.
BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr.
4-Antibody AG today announced that Dr. Richard Mason has joined the company as Chief Executive Officer and Geschaeftsfuehrer. Dr. Mason joins 4-Antibody from venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an Executive-in-Residence. Previously Dr.
MRC Technology (MRCT) (London, UK) and Biolex Therapeutics, Inc. (Pittsboro, North Carolina, USA) announced today that MRCT had successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.